We compared the incidence of early infectious complications between matched related (MR) and matched unrelated/mismatched (MU/MM) allogeneic stem cell transplant (allo-SCT) recipients in a single centre over a 6-year period in 214 consecutive adult patients. Early infections were defined as occurring from hospital admission for SCT until discharge. One hundred and fifty-nine patients received an allograft from MR donors and 55 patients received MU/MM allo-SCT. One hundred and eight of 214 patients had 147 episodes of fever. Ninety-three episodes (63%) were due to clinically or microbiologically documented infections and 54 episodes (37%) to fever not related to infection. Patients undergoing MU/MM transplantation tended to have more documented infections compared to recipients of MR allo-SCT (P = 0.06). Significantly more MU/MM transplant recipients had breakthrough infections with Herpes simplex virus type 1 (HSV-1, P = 0.003), and more CMV reactivation (P = 0.015). The mortality rate in all patients during hospitalisation post-SCT was 6.3% in MR and 18.2% in MU/MM allo-SCT recipients (P = 0.009). Early mortality was associated with infection in 70% of the patients, with a similar distribution between MR and MU/MM transplant recipients. However, MU/MM transplant recipients had significantly more early deaths due to toxic causes (P Ͻ 0.001). We conclude that early post-transplant MU/MM transplant recipients tend to have more documented infections, and have significantly more breakthrough infections with HSV-1 and more CMV reactivation. MU/MM transplant recipients are at higher risk of early mortality, especially due to toxic causes.
Patients receiving allogeneic stem cell transplantation (allo-SCT) are at risk of severe infectious complications posttransplant. [1] [2] [3] Early infections can be mainly attributed to neutropenia and to microbial invasion due to the breakdown of mucosal barriers. After engraftment, infections may result from graft-versus-host disease (GVHD) and its treatment with immunosuppressives or from incomplete immune reconstitution.
Currently stem cell transplants from matched unrelated (MU) donors or mismatched related (MM) donors are increasingly used as therapy for a variety of haematological disorders. [4] [5] There is some evidence that MU/MM allo-SCT recipients suffer from more frequent and more severe infections than sibling allograft patients, 6 -10 but it is not entirely clear whether this difference already emerges in the early period post-transplant. In this study we compare the incidence of early clinically and microbiologically documented infections between adult patients who have undergone matched related (MR) and those who have undergone MU/MM allo-SCT.
Patients and methods

Patients
We reviewed the infectious complications that occurred from hospital admission until discharge of 214 consecutive adult patients who underwent allogeneic transplantation between January 1994 and December 1999. All patients were available for analysis. One hundred and fifty-nine patients received an allograft from a MR donor, 43 patients received an allo-SCT from a MU donor and 12 patients received a one-mismatch allo-SCT from a sibling donor. Patients eligible for allo-SCT were in remission or had a responsive relapse. All patients were treated for a haematological malignancy or severe aplastic anaemia.
Conditioning regimens and GVHD prophylaxis
One hundred and fifty-seven patients were treated with cyclophosphamide 60 mg/kg once daily i.v. for 2 days fol-Bone Marrow Transplantation lowed by two doses of 6 Gy of total body irradiation (TBI). In cases of MM/MU allo-SCT, patients also received antithymocyte globulin (ATG) 4 mg/kg i.v. for 5 days before starting cyclophosphamide (n = 54). Three patients received an alternative conditioning regimen. As prophylaxis for GVHD, all transplant recipients received partial T celldepleted (1 to 2 ϫ 10 5 T cells/kg) donor marrow and cyclosporine 3 mg/kg/24 h i.v. from day Ϫ3 until 3 weeks after transplantation, and subsequent oral cyclosporine was tapered from 2 months in the absence of acute GVHD. 11 Acute GVHD was identified clinically and graded as stages I-IV using Seattle criteria.
Antimicrobial prophylaxis and other preventive measures
Anti-infection prophylaxis 12, 13 is summarized in Table 1 . Patients were nursed in a single room with free entry for staff and visitors. Careful washing of the hands with alcohol solution and the use of low count microbial food were the only preventive measures used in these patients. Intravenous access was achieved by a double-or triple-lumen tunnelled central venous catheter.
Definition of infection and antimicrobial therapy
Infectious complications were identified in several ways. Before initiation of cytotoxic treatment samples from oral washings, urine, faeces and relevant lesions were obtained for determination of the baseline flora and thereafter at least once weekly during the entire granulocytopenic period. Routinely, patients were examined daily for signs of infection. In cases of fever or suspicion of infection, additional cultures were taken from blood, oral washings, sputum, urine and skin lesions, and X-ray examination of the chest was performed. Isolated febrile episodes were defined as an oral body temperature of Ͼ38ºC for at least 1 h or a single oral temperature of Ͼ38.3ºC.
14 Early infections were defined as infections occurring from allo-SCT until discharge. Unexplained fever was defined as persistent fever above 38ºC without clinical or microbiological evidence of infection. Infections were classified as microbiologically Table 1 Antimicrobial prophylaxis
Antimicrobial prophylaxis Duration
Ciprofloxacin oral 500 mg twice a day from admission until granulocytes Ͼ500 ϫ 10 6 /l Cephalotin i.v. 1 g six times a day from day 3 posttransplant for у10 days during mucositis episode Amphotericin B oral 200 mg four times a day from admission until granulocytes Ͼ500 ϫ 10 documented when microorganisms could be recovered from the site of infection or from the blood, and as clinically documented when signs and symptoms of infection were present without positive cultures. Mucositis and diarrhoea without isolated pathogens were not considered as infection. For coagulase-negative staphylococci, more than one positive culture with the same antibiogram was required to diagnose bacteraemia and rule out skin contamination. 15 When patients had a suspected infection and/or fever, empirical monotherapy with imipenem-cilastatin was initiated, while prophylaxis with ciprofloxacin and antifungal agents was continued. 
Statistics
Continuous variables were compared using the Student's ttest. Categorical data were analysed using the Fisher exact test or a chi-square test. All P values are two-tailed. Significance indicated a P value р0.05.
Results
Patient characteristics
Charts were available for all 214 patients. Patient characteristics are shown in Table 2 .
All MR allo-SCT recipients engrafted primarily. Three MU/MM allo-SCT recipients had delayed engraftment (Ͼ35 days). Another three patients undergoing MU/MM allo-SCT had primary graft failure; two of them received SCT = stem cell transplantation; MR = matched related; MU/MM = matched unrelated/mismatched; AML = acute myeloid leukaemia; ALL = acute lymphoblastic leukaemia; CML = chronic myeloid leukaemia; NHL = non-Hodgkins' lymphoma; SAA = severe aplastic anaemia; MDS = myelodysplastic syndrome; TBI = total body irradiation; ATG = anti-thymocyte globulin; BMT = bone marrow transplantation; PBSCT = peripheral blood stem cell transplantation; CMV = cytomegalovirus; aGVHD = acute graft-versus-host disease.
bone marrow re-infusion from the donor without success. All three patients died due to infectious and/or toxic complications.
Infections
One hundred and eight of 214 patients (50%) developed 147 febrile episodes during hospitalisation for SCT until discharge (Table 3) , with no significant difference between patients undergoing MR and MU/MM allo-SCT. Twentyfour of 159 (15%) MR allo-SCT recipients developed fever for a second time, as well as 15 of 55 (27%) MU/MM transplant recipients (P = 0.07). Ninety-three (63%) febrile episodes were due to clinically or microbiologically documented infections. Since some patients had a combination of a clinical and microbiological infection or more than one microbiological infection at the same time, a total of 105 clinically (n = 39) and microbiologically (n = 66) documented infections were found in 93 febrile episodes.
Bone Marrow Transplantation Fifty-four (37%) febrile episodes could not be attributed to infection. In addition 13 allo-MR SCT recipients and 10 patients who underwent allo-MU/MM SCT had a clinically or microbiologically documented infection without fever. Thus, in 214 allo-SCT recipients a total of 128 infections were documented, 89 in 159 MR transplant recipients and 39 in 55 allo-MU/MM SCT recipients (P = 0.06). Fiftythree infections (41%) were classified as clinically documented infections and a causative micro-organism could be detected in 75 infectious episodes (59% , Tables 4 and 5) .
Bacterial infections
Overall, gram-positive bacteria accounted for 69% of the Table 4 Clinically and microbiologically documented early infections in allogeneic SCT recipients microbiologically documented infections (Table 5) . Coagulase-negative staphylococcus was the predominant pathogen cultured, and central line associated infections were the predominant cause of bacterial infections. The microbiological cause of pneumonia could be identified in 10 out of 27 patients (37%). In two patients only could pulmonary infections be related to bacteria. One patient developed pneumonia caused by S. aureus, which occurred after cessation of ciprofloxacin. Another patient had pneumonia with H. influenzae, cultured in both sputum and blood.
Thirty patients had bacteraemia, evenly distributed between MR and MU/MM transplant recipients, and predominantly caused by coagulase-negative staphylococci (n = 20). Five patients with a bacteraemia developed infection with Streptococcus spp. Three patients had a bacteraemia with a Streptococcus mitis strain, with diminished susceptibility (n = 1) or resistance (n = 2) to cephalotin, but without sequelae. Two episodes of bacteraemia were due to Gramnegative rods, one due to a ciprofloxacin resistant Escherichia coli and one due to a ciprofloxacin sensitive E. coli strain in a patient no longer using ciprofloxacin. Furthermore, two episodes of bacteraemia were caused by Enterococcus sp., and one patient had a bacteraemia with Bacillus cereus.
Other infections included urinary tract infections in two patients due to Enterococcus spp., and in one patient due to Proteus mirabilis, after cessation of ciprofloxacin.
Six patients developed a gastrointestinal tract infection. One patient had clinical diverticulitis and one patient had a perianal infection caused by Enterococcus spp. In four patients with enterocolitis Clostridium difficile (three strains were toxin positive) was cultured.
Fungal infections
In total, 16 patients (7.5%) received empirical amphotericin B intravenously, 10 who had received MR allo-SCT and six who had undergone MU/MM allo-SCT. Eight patients (4%) received prophylactic intravenous amphotericin B from start of conditioning until neutrophil recovery because of proven or probable aspergillus infection in the past. The patients who were empirically treated with amphotericin B i.v. had a significantly longer mean duration of granulocytopenia than patients who were not treated or who were prophylactically treated with amphotericin B (25 vs 20 days, P = 0.007). There were seven cases of invasive aspergillosis (four proven and three probable) in 214 patients (3%), all with pulmonary involvement. One of these seven patients had a history of invasive aspergillosis and developed a recurrence despite prophylactic therapy with amphotericin B i.v. There was no association between invasive fungal infection and transplant type, patients' age, underlying disease, or aGVHD. None of the patients developed an invasive infection with candida.
Viral infections
Two patients had pneumonia due to a virus infection with influenza A, cultured from bronchoalveolar lavage samples. Ten patients had an infection with HSV-1 and one with VZV despite acyclovir (n = 9) or valaciclovir (n = 2) prophylaxis. Eight patients had a mucocutaneous infection and two patients had pneumonia with HSV-1. Seven patients (13%) with HSV-1 infection were recipients of MU/MM allo-SCT (prophylaxis with 5 mg/kg i.v. acyclovir three times a day) compared to three patients (2%) with HSV-1 in MR-transplant recipients (prophylaxis with oral acyclovir (n = 1) or valacyclovir (n = 2), P = 0.003). Eight patients had resolution of HSV-1 lesions after high-dose (10 mg/kg, three times a day) acyclovir i.v. Two patients needed therapy with foscarnet.
Two other patients were clinically suspected to have viral meningo-encephalitis, but culture or PCR of cerebrospinal fluid did not reveal HSV-1. Both patients died despite adequate antiviral and antibacterial therapy.
Early CMV reactivation (measured by immediate-early antigen test) during the period of hospitalisation after SCT occurred in eight (8%) CMV seropositive recipients; three of 77 (4%) CMV-seropositive MR allo-SCT recipients vs five of 23 (22%) CMV-seropositive MU/MM allo-SCT recipients (P = 0.015). All patients with a positive CMV-IEA test received pre-emptive therapy with ganciclovir. None of them developed CMV disease.
Mortality
The mortality rate of all patients from admission for SCT until discharge was 9.3% (20 of 214 patients), with a significant difference between MR and MU/MM allo-SCT recipients (P < 0.01, Table 6 ). Infection was associated with early mortality in 70% (14 of 20) of the patients, but no significant difference in death related to infection was noted between MR and MU/MM transplant recipients. Eight patients with a fatal infection had a suspected or proven invasive aspergillosis infection; seven patients with pulmonary aspergillosis and one with cerebral aspergillosis diagnosed after death. We observed that mortality from toxic causes occurred only in the MU/MM allo-SCT group (P Ͻ 0.001), and was often related to aGVHD. We did not find a relation between early death and age, underlying disease, aGVHD, or sex, but there was a significant difference in mean duration of granulocytopenia (P = 0.005) between patients who died during their hospital admission and those who did not. Apart from the three patients who died due to non-engraftment, all patients who died early had granulocyte engrafted Ͼ0.5 ϫ 10 9 /l.
Discussion
We have compared the incidence of early infectious complications between patients who underwent MR and MU/MM allo-SCT in a single centre over a 6-year period. The major risk factor reported in the literature that is associated with early infectious complications in allogeneic Table 6 Causes of early mortality in allogeneic SCT recipients 
Causes of early mortality allo-SCT allo-SCT
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SCT is time to engraftment. 1, 2, 16, 17 In our study we found a significant difference in duration of neutropenia between MR and MU/MM allo-SCT recipients, which was reflected in a tendency to more infectious complications in the latter group. As additional risk factors, MU/MM allo-SCT recipients were more often in second remission and had had more preceding courses of cytoreductive therapy. Moreover, MU/MM allograft patients had received a different conditioning regimen, including ATG. Other studies have also reported positive recipient CMV serology, 10 use of a T celldepleted allograft 18 and occurrence of aGVHD 3 as risk factors for early infections, primarily because these factors may have an influence on the duration of neutropenia. However, we found no difference in these risk factors between MR and MU/MM allo-SCT recipients.
The majority of early infectious complications in our study consisted of bacterial infections, with no difference in incidence between MR and MU/MM all0-SCT recipients. As in other reports, 8, 10, 19 Gram-positive bacteria, especially coagulase-negative staphylococci, were the predominant pathogens cultured in cases of microbiologically documented infections. With our prophylactic regimen of cephalotin, we found a low incidence of viridans streptococci compared to other reports, 8, 10 but awareness of infection with resistant strains of viridans streptococci is necessary. Only four infections were caused by Gram-negative bacteria, reflecting the efficacy of prophylaxis with ciprofloxacin, yet one E. coli strain was resistant to ciprofloxacin.
This study supports other observations that fungal infections still constitute a problem after allo-SCT. The therapy of invasive fungal infections is often unsuccessful, and fungal infections have been reported to have a mortality of Ͼ90% in SCT recipients. 20 The contribution of neutropenia to invasive fungal infections is an approximately 15% incidence after therapy of acute leukaemia or marrow transplantation. 21, 22 Most aspergillus infections in allo-SCT recipients occur late after transplantation and are associated with acute or chronic GVHD and its treatment with immunosuppressives. 7, 22 In our study MU/MM allo-SCT recipients received more, but not significantly so, empirical intravenous amphotericin B than did patients who had undergone MR allo-SCT. Also, early aspergillus infections were not associated with transplant type. Yet all patients with a proven or probable aspergillus infection that occurred after transplantation died. Methods for early detection of invasive aspergillosis and new therapeutic options are therefore pivotal. Blood samples from patients can be tested for antigens against aspergillus and polymerase chain reaction to demonstrate fungal DNA, but the clinical value of these tests remains to be established. 23, 24 Recently, promising data have been shown concerning detection of pulmonary aspergillosis by polymerase chain reaction in broncho-alveolar lavage samples of neutropenic patients. 25 Invasive candida infections will occur mainly during the neutropenic period. 26 None of our patients had an invasive candida infection, and it appears that our prophylactic regimen of oral fluconazole and oral amphotericin B successfully prevented severe candidiasis. We did not encounter problems with fluconazole resistant candida species, such as C. krusei, but we found a small but gradual shift from C. albicans to non-albicans Candida species in surveillance cultures, as was reported in previous studies. 27, 28 In particular herpes viruses caused viral infections, but two patients had pneumonia with influenza A virus. Community respiratory viruses such as RSV, influenza and parainfluenza, have emerged as significant causes of morbidity in SCT recipients. 29 In our study, seven of 10 patients who experienced a HSV-1 infection were recipients of MU/MM transplantation. Clinical failure of acyclovir prophylaxis does not always reflect virological resistance -in cases of oral administration, patient compliance is mandatory -but acyclovir-resistant HSV-1 infections have been documented. 30, 31 Since acyclovir-resistant strains have little virulence in the immunocompetent and are more common in immunocompromised patients, recipients of MU/MM allo-SCT may be more at risk of acquiring breakthrough infections with HSV than patients who have undergone MR allo-SCT. We therefore changed our prophylactic regimen for these patients from i.v. acyclovir 5 mg/kg to 10 mg/kg three times a day.
Although seropositivity for CMV was equally distributed between recipients of MR and MU/MM transplants, significantly more patients who received MU/MM allo-SCT had positive CMV-IEA tests early post-transplant. Both the occurrence of more breakthrough infections with HSV-I and the more frequent CMV reactivation in MU/MM allo-SCT recipients probably reflect the use of ATG in the conditioning regimen.
We found a statistical difference in early mortality rates in our study population between MR and MU/MM allo-SCT recipients. In contrast to the rather low mortality in MR donor recipients, 20% of patients who underwent MU/MM transplantation died early, particularly from toxic complications. A comparable mortality rate of 25% in the first 100 days after transplantation in unrelated donor transplant recipients was reported by Williamson et al. 8 Not surprisingly, this study also showed that the duration of neutropenia was associated with early infection-related death, especially in MU/MM allo-SCT recipients. Faster engraftment in MU/MM transplant recipients could be of importance and may be achieved by growth factors or more likely by peripheral blood stem cell transplantation. 32, 33 In conclusion, patients receiving MU/MM allo-SCT tend to have more clinically and microbiologically documented infections, and have significantly more breakthrough infections with HSV-1 and early CMV reactivation. MU/MM allo-SCT recipients are at higher risk of early mortality, especially due to toxic causes.
